Search Results

June 2022 "Published on juin 22, 2022 On June 22, 2022, Michel Bouvier, Chief Executive Officer of IRIC, Principal Investigator of the Molecular Pharmacology Research Unit and Professor in the Department of Biochemistry and Molecular Medicine of the Faculty of Medicine of the Université de Montréal, is appointed Knight of the Ordre national du Québec. This honorary decoration, bestowed today by the government of Quebec, is the highest honour in Quebec aimed at promoting excellence. It has been awarded annually since 1985 to distinguished individuals who have strived, in an exceptional way, to enhance Quebec’s image. The rank of Knight specifically rewards the implementation of an exemplary activity in a particular field." Read more at the source #DrGPCR #GPCR #IndustryNews

June 2022 "CRN04894 Selected for Oral Presentation SAN DIEGO, June 8, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational candidate for the treatment of Cushing’s disease, congenital adrenal hyperplasia (CAH) and other conditions driven by excess adrenocorticotropic hormone (ACTH), were selected for an oral presentation at ENDO 2022, the Endocrine Society’s annual meeting. Crinetics recently reported that administration of CRN04894 reduced both serum cortisol levels and 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations in multiple-ascending dose cohorts of a Phase 1 study." Read more at the source #DrGPCR #GPCR #IndustryNews

June 2022 "We’re delighted to welcome Dr Ed Brennan as our new Vice President, Head of Clinical Development. Dr Brennan has extensive experience across all phases of clinical development, and across multiple therapeutic areas, including Oncology, Infectious Diseases, Immunology and Critical Care. He has led teams that have filed more than 10 Investigational New Drug Applications (IND), as well as multiple New Drug (NDA) and Supplemental New Drug Applications (SNDA). Previous companies worked at include OrthoBiotech (OBI), a division of Johnson & Johnson and GlaxoSmithKline Consumer Healthcare, L.P. In 2007 he formed IndiPharm which was a full-service Contract Research Organization whose operational headquarters were in Mumbai, India. In 2016 the company was sold to Velocity fund partners and has been rebranded as InClinica. He received his undergraduate Bachelor of Science Degree in Pharmacy from The Philadelphia College of Pharmacy and Science. He went on to study medicine at the Royal College of Surgeons in Ireland before receiving his Medical Degree from Temple University – Lewis Katz School of Medicine. #biotech #lifesciences #appointment #GPCR #Oncology" Read more at the source #DrGPCR #GPCR #IndustryNews

May 2022 Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery "Collaboration is part of Sosei Heptares’ Target Identification and Validation (TIV) strategy to leverage multiple sophisticated technologies that drive creation of new drug discovery programs in key therapeutic areas Kallyope, pioneers in drug discovery involving the gut-brain axis, will gain unique and valuable access to the Sosei Heptares compound library for its industry-leading biology platform to identify potential GPCR targets and advance the development of new gastrointestinal therapeutics Tokyo, Japan, Cambridge, UK and New York, USA – May 17, 2022 – Sosei Group Corporation, the international biopharmaceutical company, and New York City-based Kallyope, pioneers in drug discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor (GPCR) targets with a goal of creating new drug discovery programs in the area of gastrointestinal diseases. " Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 "By Sophie Bradley | Apr 12, 2022 Summary Sophie Bradley, Translational Sciences Associate Director at Sosei Heptares, recently presented at the Keystone Symposia GPCR Conference, a summary of work performed both at Sosei Heptares and Glasgow University characterizing the role of the muscarinic M1 receptor in cognitive and neurodegenerative disorders and the potential therapeutic benefit of muscarinic M1 selective ligands." Read more at the source #DrGPCR #GPCR #IndustryNews

May 2022 "MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces the appointment of Glenn S. Vraniak to the position of Chief Financial Officer (CFO), effective immediately. Mr. Vraniak’s career spans more than 20 years of financial and commercial experience in the life sciences industry. Before joining Inversago, Mr. Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company and led the company through a successful IPO on Nasdaq in February 2021, and successfully raised follow-on capital later that same year. Prior to that, Mr. Vraniak served as the Chief Financial Officer of electroCore, Inc. and was a key member of the management team that led the company through a successful IPO on Nasdaq in June 2018. Additionally, Mr. Vraniak served as an executive in various innovative healthcare and technology companies including GE Capital, where he served as Executive Vice President." Read more at the source #DrGPCR #GPCR #IndustryNews

May 2022 "We are thrilled to announce that our co-founder Margaux Duchamp has been selected as a 30 under 30 Europe Forbes ranking 2022 for science and healthcare. #ForbesUnder30 #ArcoScreen #sciences #EPFL" Read more at the source #DrGPCR #GPCR #IndustryNews

May 2022 "Seoul, South Korea, 28 April 2022 – GPCR therapeutics, Inc., a venture-backed clinical stage international biopharmaceutical company with an innovative approach to drug discovery based on targeting G Protein Coupled Receptors (GPCR) pairs, today announced four appointments to its Scientific Advisory Board (SAB). Dr. Michel Bouvier, Dr. Luisa Salter-Cid, Dr. Omar Nadeem and Dr. Jon Wigginton will provide scientific expertise to support the company’s research and clinical development. GPCR just had a very successful first meeting including all the Scientific Advisory Board." Read more at the source #DrGPCR #GPCR #IndustryNews

May 2022 "Published: May 10, 2022 To accelerate clinical development of its best-in-class and first-in-class immuno-oncology programs STRASBOURG, France & MONTREAL- Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, announced today the closing of a US $42m (€39m) series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to treat pain without the negative side effects "Many people are familiar with cannabis, but John Streicher, PhD, takes a closer look at the plant’s aromatic chemical compounds called terpenes. These compounds may be a novel way to treat pain without the negative side effects of cannabinoids or opioids." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 "By Cliona MacSweeney | Apr 20, 2022 Cliona MacSweeney, a project director in our Translational Medicine department, recently presented this important pre-clinical work at SIRS2022 confirming the ability of the highly selective novel GPR52 agonist HTL00411718 to modulate centrally mediated locomotor activity in response to A2A receptor antagonists. This work highlights an important interplay between the adenosinergic and dopaminergic systems and suggests the potential for GPR52 agonists to control neuropsychiatric symptoms in conditions such as schizophrenia. " Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of Ultrahigh Throughput Drug Discovery Platform "April 12, 2022 07:00 AM Eastern Daylight Time CAMBRIDGE, Mass.--Design Pharmaceuticals, a company redesigning small molecule drug discovery, today announced the closing of a pre-series A round of $5 million, including an investment of $3 million from Virtus Inspire Venture Partners. The proceeds will be used to further build the company’s discovery platform and operations. Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like molecules from natural sources, such as microbiota. These molecules are then evaluated at unprecedented speed and scale on hundreds of GPCR targets simultaneously." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 per share. All of the shares to be sold in the offering are to be sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $125.0 million. The offering is expected to close on or about April 18, 2022, subject to the satisfaction of customary closing conditions." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group "CHESTERBROOK, Pa., March 31, 2022 -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the Company entered into a royalty-based financing with an affiliate of R-Bridge Healthcare Fund (the R-Bridge Financing)." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund "CHESTERBROOK, Pa., April 18, 2022 - Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced receipt of the first $15 million tranche from its royalty-based financing agreement with an affiliate of R-Bridge Healthcare Fund (the R-Bridge Financing)." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage of its Evolution "New team focused on expanding its GPCR-focused structure-based drug design platform and enhancing translational medicine capabilities • ‘Venture-like’ capital allocation approach to focus pipeline development through to Phase 1b/2a clinical proof of concept in patients, and optimize value generation • Mid-term global expansion plans include drug discovery technology investments, licensing late-stage products for Japan, and strategic acquisitions • Mr. Chris Cargill appointed as President and Chief Executive Officer • Dr. Matt Barnes appointed President of Heptares Therapeutics Ltd., and Head of UK R&D Tokyo, Japan and Cambridge, UK, 24 March 2022 – Sosei Group Corporation (“the Company”; TSE: 4565) today confirms that a series of Executive Management changes have been approved at the Company’s 32nd Shareholders’ Meeting today and are effective immediately (see biographies at the end)." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics "Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the pharmacology known as allosteric modulation. This emerging class of small molecule drugs known as allosteric modulators is being explored for treating central nervous system and neurologic disorders, particularly movement disorders like dyskinesia associated with Parkinson's and dystonia. Addex did not invent allosteric modulation but is pioneering the screening technologies to find these difficult to locate molecules." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment Of Schizophrenia & Other Psychotic Disorders "New Series of Potent and Selective Compounds Identified Using Proprietary Allosteric Modulator Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 6, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it has moved a selective and potent M4 muscarinic receptor positive allosteric modulator (PAM) program into lead optimization. M4 PAMs have the potential to treat schizophrenia and other types of debilitating neuropsychiatric disorders." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical Study "Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that patient enrollment has been completed in its Phase 2a clinical study evaluating dipraglurant as a potential treatment for blepharospasm, a type of dystonia characterized by involuntary contractions or spasms of the eyelid muscles. Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm." Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Of Neuropathic Pain "— Confo’s first drug candidate moves into clinical development — Ghent, Belgium – March 10, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first subjects have been dosed in the company’s Phase 1, first-in-human trial of their clinical candidate CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R). CFTX-1554 is being developed as a non-opioid approach to the treatment of neuropathic pain, a debilitating condition caused by damage to the nerves outside of the brain and spinal cord, for which current treatment methods are often insufficiently effective and can lead to serious side effects and addiction. The Phase 1 study will assess the safety, tolerability and pharmacokinetics of CFTX-1554 in healthy subjects (NCT05260658). " Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial "MONTREAL (CANADA) – March 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome in a Phase 1b clinical trial. This 28-day trial will test the pharmacokinetics and safety profile of Inversago’s lead molecule, INV-202, on a targeted population with metabolic syndrome. Topline results from 40 subjects are expected in the second half of the calendar year." Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 "Congratulations to Richard J. Law, our newly named Chief Business Officer. Richard is the architect behind nearly all of Exscientia's partnerships and collaborations across pharma and #biotech⁠ and is an advocate for the role of #AI in drug discovery." Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 "Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in immunoresistance, to develop first-in class innovative cancer therapies. Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement. The two companies will combine their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough therapeutic programs for IO. Financial terms are not disclosed." Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief Commercial Officer "SAN DIEGO – March 1, 2022 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of James Hassard as chief commercial officer. Mr. Hassard is a commercial leader with more than three decades of experience leading sales and marketing operations for both global and domestic biotechnology companies." Read more at the source #DrGPCR #GPCR #IndustryNews

Are you ready? Tomorrow is the day for another Dr. GPCR Virtual Cafe. This time with none other than Dr. Bryan Roth There are 10 open tickets available. Get yours now! https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

Mark your calendars! The Dr. GPCR Podcast is back this week with a brand new episode. Our guest is none other than Dr. Juan Jose Fung, Principal Scientist, at GPCR Therapeutics. Stay tuned as the episode will be released later this week. Subscribe today! https://buff.ly/32fzGbO #gpcr #drgpcr #podcast

Next on the Dr. GPCR Podcast, we have none other than Dr. Marta Filizola! Subscribe to the podcast today and get notified when new episodes are released! You can also leave us a review on Apple Podcast! https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ #gpcr #drgpcr #podcast

Mark your calendars and get your ticket today! The Dr. GPCR Virtual Cafe is back! Our first guest speaker is none other than Dr. Ben Myers! Learn about communication between GPCRs and PKA, Class F GPCR Smoothened & the Hedgehog signaling pathway! https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe

Next on the Dr. GPCR Podcast, we have Dr. Pina Cardarelli, CSO of GPCR Therapeutics. Subscribe to the podcast today and get notified when new episodes are released! ecosystem.drgpcr.com/dr-gpcr-podcast/ #gpcr#drgpcr #podcast